Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality - PubMed (original) (raw)
Clinical Trial
. 2001 Dec 15;98(13):3595-9.
doi: 10.1182/blood.v98.13.3595.
R M Saliba, S A Giralt, M S Lee, G J Okoroji, F B Hagemeister, M Korbling, A Younes, C Ippoliti, J L Gajewski, P McLaughlin, P Anderlini, M L Donato, F F Cabanillas, R E Champlin
Affiliations
- PMID: 11739162
- DOI: 10.1182/blood.v98.13.3595
Free article
Clinical Trial
Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality
I F Khouri et al. Blood. 2001.
Free article
Abstract
This study investigated the use of a nonablative conditioning regimen to decrease toxicity and achieve engraftment of an allogeneic blood stem cell transplant, allowing a graft-versus-malignancy effect to occur. All patients had follicular or small cell lymphocytic lymphoma after relapse from a prior response to conventional chemotherapy. Patients received a preparative regimen of fludarabine (25 mg/m(2) given daily for 5 days or 30 mg/m(2) daily for 3 days) and intravenous cyclophosphamide (1 g/m(2) given daily for 2 days or 750 mg/m(2) daily for 3 days). Nine patients received rituximab in addition to the chemotherapy. Tacrolimus and methotrexate were used for graft-versus-host disease (GVHD) prophylaxis. Twenty patients were studied; their median age was 51 years. Twelve were in complete remission (CR) at transplantation. All patients achieved engraftment of donor cells. The median number of days with severe neutropenia was 6. Only 2 patients required more than one platelet transfusion. The cumulative incidence of acute grade II to IV GVHD was 20%. Only one patient developed acute GVHD of greater than grade II. All patients achieved CR. None have had a relapse of disease, with a median follow-up period of 21 months. The actuarial probability of being alive and in remission at 2 years was 84% (95% confidence interval, 57%-94%). Nonablative chemotherapy with fludarabine/cyclophosphamide followed by allogeneic stem cell transplantation is a promising therapy for indolent lymphoma with minimal toxicity and myelosuppression. Further studies are warranted to compare nonablative allogeneic hematopoietic transplantation with alternative treatment strategies.
Similar articles
- Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
Tomblyn MR, Ewell M, Bredeson C, Kahl BS, Goodman SA, Horowitz MM, Vose JM, Negrin RS, Laport GG. Tomblyn MR, et al. Biol Blood Marrow Transplant. 2011 Jul;17(7):1051-7. doi: 10.1016/j.bbmt.2010.11.004. Epub 2010 Nov 10. Biol Blood Marrow Transplant. 2011. PMID: 21073974 Free PMC article. Clinical Trial. - Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.
Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Khouri IF, et al. Blood. 2008 Jun 15;111(12):5530-6. doi: 10.1182/blood-2008-01-136242. Epub 2008 Apr 14. Blood. 2008. PMID: 18411419 Free PMC article. Clinical Trial. - Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
Laport GG, Wu J, Logan B, Bachanova V, Hosing C, Fenske T, Longo W, Devine SM, Nademanee A, Gersten I, Horowitz M, Lazarus HM, Riches ML; Blood and Marrow Transplant Clinical Trials Network. Laport GG, et al. Biol Blood Marrow Transplant. 2016 Aug;22(8):1440-1448. doi: 10.1016/j.bbmt.2016.04.014. Epub 2016 Apr 23. Biol Blood Marrow Transplant. 2016. PMID: 27118571 Free PMC article. Clinical Trial. - Allogeneic stem cell transplantation in follicular lymphoma.
Khouri IF. Khouri IF. Best Pract Res Clin Haematol. 2011 Jun;24(2):271-7. doi: 10.1016/j.beha.2011.03.008. Epub 2011 May 5. Best Pract Res Clin Haematol. 2011. PMID: 21658623 Free PMC article. Review. - Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, Deliliers GL, Martino R, Russell N, Van Biezen A, Michallet M, Niederwieser D; Chronic Leukemia Working Party of the EBMT. Dreger P, et al. Leukemia. 2003 May;17(5):841-8. doi: 10.1038/sj.leu.2402905. Leukemia. 2003. PMID: 12750695 Review.
Cited by
- High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas.
Ramdial J, Lin R, Thall PF, Valdez BC, Hosing C, Srour S, Popat U, Qazilbash M, Alousi A, Barnett M, Gulbis A, Shigle TL, Shpall EJ, Andersson BS, Nieto Y. Ramdial J, et al. Bone Marrow Transplant. 2024 Sep 28. doi: 10.1038/s41409-024-02394-0. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 39341929 - Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies.
Tomaszewska A, Jagasia M, Beohou E, van der Werf S, Blaise D, Kanfer E, Milpied N, Reményi P, Ciceri F, Bourhis JH, Chevallier P, Solano C, Socié G, Bruno B, Rambaldi A, Castagna L, Kröger N, Corradini P, Afanasyev B, Ladetto M, Niederwieser D, Scheid C, Sengeloev H, Kroschinsky F, Yakoub-Agha I, Schoemans H, Koenecke C, Penack O, Perić Z, Greinix H, Duarte RF, Basak GW. Tomaszewska A, et al. Front Immunol. 2021 Feb 2;11:613954. doi: 10.3389/fimmu.2020.613954. eCollection 2020. Front Immunol. 2021. PMID: 33603743 Free PMC article. - Alternative donor transplants for severe aplastic anemia.
Bacigalupo A. Bacigalupo A. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):467-473. doi: 10.1182/asheducation-2018.1.467. Hematology Am Soc Hematol Educ Program. 2018. PMID: 30504347 Free PMC article. Review. - Fludarabine as a cost-effective adjuvant to enhance engraftment of human normal and malignant hematopoiesis in immunodeficient mice.
Pievani A, Michelozzi IM, Rambaldi B, Granata V, Corsi A, Dazzi F, Biondi A, Serafini M. Pievani A, et al. Sci Rep. 2018 Jun 14;8(1):9125. doi: 10.1038/s41598-018-27425-x. Sci Rep. 2018. PMID: 29904072 Free PMC article. - Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.
Merryman RW, Armand P, Wright KT, Rodig SJ. Merryman RW, et al. Blood Adv. 2017 Dec 12;1(26):2643-2654. doi: 10.1182/bloodadvances.2017012534. eCollection 2017 Dec 12. Blood Adv. 2017. PMID: 29296917 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources